Table 2:

Demographic and clinical summaries of the combined participants in the study broken down by sex. Bolded test statistics signify statistical differences between male and female groups at a 0.05 level of significance.

Characteristic	Males	Females	Test Statistic
Total Participants, n (%)	31 (38.7)	49 (61.3)	${\mathit{\chi }}_{\mathbf{1}}^{\mathbf{2}}$ = 7.23, p = 0.007
Age, Mean (SD)	66.06 (8.5)	66.27 (5.5)	t58 = −0.12, p = 0.905
Black/African American, n (%)	4 (12.9)	11 (22.4)	${\chi }_1^2$ = 0.60, p = 0.480
Education Years, Mean (SD)	15.77 (2.7)	15.04(2.5)	t58 = 1.17, p = 0.248
Treatment, n (%)	Escitalopram 9 (29.0) Levomilnacipran 4 (12.9) Venlafaxine 18 (58.1)	Escitalopram 14 (28.6) Levomilnacipran 2 (4.1) Venlafaxine 33 (67.3)	${\chi }_1^2$ = 0, p = 1.000
Baseline MADRS, Mean (SD)	25.81 (7.0)	23.19 (6.3)	t58 = 1.68, p = 0.099
CIRS-G, Mean (SD)	9.80 (3.6)	9.30 (4.6)	t58 = 0.54, p = 0.592
Remitters, n (%)	12 (38.7)	30 (61.2)	${\chi }_1^2$ = 3.01, p = 0.083